GlaxoSmithKline is not planning to exit the U.K. just because the U.K. is exiting the European Union. As if to emphasize its commitment, the drugmaker said it intends to put a big chunk of money into expanding its manufacturing there.

China's efforts in good manufacturing practice certification in 2015 showed a continued shift toward warning letters even as the overall number of reviewed applications fell by more than half.

Merck & Co. is facing another supply interruption for its ovulation-stimulating hormone Follistim, and like the supply lapse from several years ago, Merck has little to say.